{
    "title": "Who can get the newly approved Eisai and Biogen Alzheimer's drug?",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11608311/Who-newly-approved-Eisai-Biogen-Alzheimers-drug.html",
    "date": "2023-01-06",
    "keywords": [
        "drug",
        "brain",
        "coverage",
        "amyloid",
        "lecanemab",
        "treatment",
        "disease",
        "medicare",
        "cms",
        "approval",
        "risk",
        "jan",
        "population",
        "leqembi",
        "agency",
        "type",
        "swelling",
        "label",
        "blood",
        "food",
        "administration",
        "co",
        "ltd",
        "biogen",
        "brainwasting",
        "brand",
        "name",
        "class",
        "progression",
        "toxic",
        "protein",
        "beta",
        "access",
        "use",
        "impairment",
        "test",
        "scan",
        "tap",
        "presence",
        "week",
        "pocket",
        "year",
        "insurance",
        "amp",
        "medicaid",
        "policy",
        "trial",
        "process",
        "healthcare",
        "plan",
        "age",
        "statement",
        "decision",
        "fda",
        "data",
        "case",
        "eisai",
        "reimbursement",
        "analyst",
        "evan",
        "seigerman",
        "drugmaker",
        "safety",
        "requirement",
        "mri",
        "course",
        "leqembis",
        "stroke",
        "tissue",
        "plasminogen",
        "activator",
        "tpa",
        "bhanvi",
        "satija",
        "raghav",
        "mahobe",
        "bengaluru",
        "julie",
        "steenhuysen",
        "chicago",
        "editing",
        "humer",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}